{
    "nct_id": "NCT05468697",
    "official_title": "A Multicenter, Open-label, Randomized, Phase 1/2 Study of Belzutifan in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma",
    "inclusion_criteria": "* Has a histologically confirmed diagnosis of unresectable Stage IV (per American Joint Committee on Cancer [AJCC], 8th Edition) RCC with clear-cell component\n* Has had disease progression on or after having received at least 2 systemic treatments for unresectable Stage IV RCC with prior anti-programmed cell death 1 ligand 1 (PD-1/L1) and a vascular endothelial growth factor-tyrosine kinase inhibitor (VEGF-TKI) in sequence or in combination\n* Has measurable disease per RECIST 1.1 as assessed by the investigator and verified by blinded independent central review (BICR)\n* Has recovered from all AEs due to previous therapies\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Has hypoxia, requires intermittent supplemental oxygen, or requires chronic supplemental oxygen\n* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years\n* Has known central nervous system (CNS) metastases and/or carcinomatous meningitis\n* Has clinically significant cardiac disease\n* Has moderate to severe hepatic impairment\n* Has a known history of human immunodeficiency virus (HIV) infection\n* Has a history of hepatitis B (HBV) or known active hepatitis C (HCV) infection\n* Has received prior treatment of belzutifan or palbociclib\n* Has received prior radiotherapy ≤2 weeks prior to first dose of study intervention. Participants must have recovered from all radiation-related toxicities and not require corticosteroids\n* Has had major surgery ≤3 weeks prior to first dose of study intervention\n* Has received colony-stimulating factors (eg, granulocyte colony-stimulating factor [G-CSF], granulocyte-macrophage colony-stimulating factor [GM-CSF], or recombinant erythropoietin [EPO]) ≤28 days prior to the first dose of study intervention",
    "miscellaneous_criteria": ""
}